- $948.24m
- $487.03m
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Jade Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Jade Biosciences Q2 net loss widens as costs rise
Brief: Jade Biosciences, Inc Q2 Cash & Investments USD 461.2 Million
Jade Biosciences Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: Jade Biosciences - Enters Exclusive Worldwide License Agreement With Paragon Therapeutics - SEC Filing
U.S. STOCKS ON THE MOVE -Honeywell, Broadcom, Carlyle
U.S. STOCKS ON THE MOVE-UnitedHealth, Pinterest, Celcuity
Jade Biosciences drops on $150 mln equity raise
Brief: Jade Biosciences Prices Public Offering Of 10 Million Shares at $15 Per Share
Jade Biosciences falls on planned equity offering
Brief: Jade Biosciences Announces Proposed Underwritten Public Offering
Brief: Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101
Brief: Jade Biosciences Announces First Participant Dosed In First-In-Human Phase 1 Clinical Trial Of Jade201
Brief: Jade Biosciences Announces First Participant Dosed In Phase 2 Juniper Clinical Trial Of Jade101 In Iga Nephropathy
Brief: Jade Biosciences Inc - Prospectus Filed For Resale Of Up To 39,542,339 Shares By Selling Stockholders - SEC Filing
U.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla
Brief: Jade Biosciences Inc - May Offer And Sell Up To $600 Million Of Securities - SEC Filing
Brief: Jade Biosciences, Inc Q1 Cash & Investments USD 311.3 Million